Efficacy and tolerability of paroxetine in patients with fibromyalgia syndrome: A single-blind study

Current Therapeutic Research - Clinical and Experimental

Volumn 60, Issue 12, 1999, Pages 696-702

  Giordano, Nicola ^a   Geraci, Simone ^a   Santacroce, Clorinda ^a   Mattii, Giancarlo ^a   Battisti, Emilio ^a   Gennari, Carlo ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Efficacy; Fibromyalgia; Paroxetine; Selective serotonin reuptake inhibitors; Tolerability

Indexed keywords

PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FIBROMYALGIA; HUMAN; MALAISE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

EID: 0033450923     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(99)90008-5     Document Type: Article

References (17)

1. 1. McCain GA. A clinical overview of the fibromyalgia syndrome. J Musculoskelet Pain. 1996;4:9-34.
2. 2. Goldenberg DL. Fibromyalgia. In: Klippel JH, Dieppe PA, eds. Rheumatology. London: Mosby; 1994:5.16.6-5.16.9.
3. 3. Bennet RM. The fibromyalgia syndrome: Myofascial pain and the chronic fatigue syndrome. In: Kelley WN, Harris ED, Ruddy S, Sledge CB, eds. Textbook of Rheumatology. Philadelphia: WB Saunders; 1993:471-473.
4. 4. Yunus MB, Masi AT. Fibromyalgia, restless legs syndrome, periodic limb movement disorder, and psychogenic pain. In: McCarty DJ, Koopman WJ, eds. Arthritis and Allied Conditions. Philadelphia: Lea & Febiger; 1993:1390-1398.
5. 5. Goldenberg D, Mayskiy M, Mossey C, et al. A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum. 1996;39: 1852-1859.
6. 6. Smith AJ. The analgesic effects of selective serotonin reuptake inhibitors. J Psychopharmacol. 1998;12:407-413.
7. 7. Nemeroff CB. Paroxetine: An overview of the efficacy and safety of a new selective serotonin reuptake inhibitor in the treatment of depression. J Clin Psychopharmacol. 1993;13(Suppl 2):10S-17S.
8. 8. Nemeroff CB. The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor. Pharmacotherapy. 1994;14:127-138.
9. 9. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: Report of the Multicenter Criteria Committee. Arthritis Rheum. 1990;33:160-172.
10. 10. Hamilton M. Hamilton Anxiety Rating Scale. Br J Psychiatry. 1964;3:76-79.
11. 11. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Psychol. 1967;6:278-296.
12. 12. Bengeston A, Backman E, Lindblom B, Skogh T. Long term follow-up of fibromyalgia patients: Clinical symptoms, muscular function, laboratory tests - an eight year comparison study. J Musculoskelet Pain. 1994;2:67-80.
13. 13. Wolfe F, Ross K, Anderson J, et al. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum. 1995;38:19-28.
14. 14. Goldenberg DL. Psychiatric and psychologic aspects of fibromyalgia syndrome. Rheum Dis Clin North Am. 1989;15:105-114.
15. 15. Goldenberg DL, Felson DT, Dinerman H. A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis Rheum. 1986;29: 1371-1377.
16. 16. Wolfe F, Cathey MA, Hawley DJ. A double-blind placebo controlled trial of fluoxetine in fibromyalgia. Scand J Rheumatol. 1994;23:255-259.
17. 17. Dequeker J, Panay G, Pincus T, Grahame R. Localized painful conditions. In: Medical Management of Rheumatic Musculoskeletal and Connective Tissue Diseases. New York: Marcel Dekker; 1997:289-291.